Selpercatinib

Selpercatinib (marketed under the brand name Retevmo) is a prescription medication used to treat certain types of cancers that have a specific genetic mutation. It belongs to a class of drugs called kinase inhibitors, which work by blocking specific enzymes that are involved in the growth and spread of cancer cells.

Selpercatinib is indicated for the treatment of:

Non-small cell lung cancer (NSCLC) that has a rearranged during transfection (RET) gene fusion

Thyroid cancer that has a RET gene mutation

Other types of cancers that have a RET gene fusion

Selpercatinib is taken orally in capsule form and is typically prescribed by a medical oncologist. It is important to follow the dosing instructions provided by the prescribing physician and to report any side effects or concerns promptly. Common side effects of selpercatinib include fatigue, constipation, diarrhea, and muscle or joint pain, among others.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancers. A small subset of NSCLC cases is caused by a genetic mutation known as a rearranged during transfection (RET) gene fusion. In these cases, the RET gene becomes abnormally fused with another gene, resulting in the production of a fusion protein that promotes cancer cell growth and survival.

Selpercatinib Controls Central Nervous System Disease in Patients With NSCLC With RET Fusion ¹⁾.